Clinical Trial Update: Combined Cumulative Irritation Potential and Repeat Insult Patch Test of LEO 90100 [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the skin irritation potential of LEO 90100 using cumulative irritation and repeat insult patch testing. The study in psoriasis vulgaris…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis Vulgaris

Drugs mentioned

• LEO 90100

Snippet

Sponsor: LEO Pharma | Conditions: Psoriasis Vulgaris | Phase 1 | Status: COMPLETED